secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001599298-23-000096
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics Q3 net loss $21.3M; starts second Phase III for ivonescimab
-------------------------------------------------------------------------------

- Net loss Q3 $21.3M; nine-month 2023 net loss $578.4M includes $520.9M one-time IPR&D charge from ivonescimab licensing.
- Cash, equivalents, and short-term investments $198.9M at Sep 30, 2023 (down from $648.6M Dec 2022); $100M notes payable due Sep 2024; expects funds into H2 2024.
- Enrollment initiated in HARMONi-3 Phase III trial for ivonescimab in first-line metastatic squamous NSCLC; HARMONi enrollment completion expected H2 2024.
- Manmeet S. Soni appointed COO and invested $5M; multiple internal promotions and hiring of Dr. Jack West and Dr. Laura Chow in clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000096/0001599298-23-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929823000096/smmt-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001599298-23-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer